CMA hits Merck for discounts
Credit: iStock/zorazhuang
The UK’s Competition and Markets Authority has provisionally found that Merck Sharp & Dohme used discounts to restrict competition from biosimilar versions of its drug Remicade.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now